Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02367040 | Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)(CHRONOS-3) | completed | Phase 3 | 458 | BayerINDUSTRY | 37 | Oct 14, 2025 | clinicaltrials |
| NCT03412773 | A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC) | completed | Phase 3 | 684 | BeiGeneINDUSTRY | 11 | Oct 14, 2025 | clinicaltrials |
| NCT04341064 |
| Sun-safe Habits Intervention and Education(SHINE) |
| completed |
| Phase 3 |
| 2,223 |
| University of UtahOTHER |
| 1 |
| Oct 14, 2025 |
| clinicaltrials |
| NCT00807027 | Clinical Trial to Assess the Efficacy and Safety of 'Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea | completed | Phase 3 | 180 | GC Cell CorporationINDUSTRY | 1 | Oct 10, 2025 | clinicaltrials |
| NCT04838626 | Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection(GuideView) | completed | Phase 2 / Phase 3 | 195 | Novartis PharmaceuticalsINDUSTRY | 5 | Oct 7, 2025 | clinicaltrials |
| NCT01812369 | Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer(VESPER) | completed | Phase 3 | 500 | University Hospital, RouenOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT02799212 | Evaluation of Postoperative Ascites After Somatostatin Infusion Following Hepatectomy for Hepatocellular Carcinoma(SOMAPROTECT01) | completed | Phase 3 | 179 | Hospices Civils de LyonOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT02201459 | Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients(PETALs) | completed | Phase 3 | 200 | Hospices Civils de LyonOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT00765440 | Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract | completed | Phase 3 | 311 | Centre Antoine LacassagneOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT03062358 | Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394) | completed | Phase 3 | 453 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Sep 30, 2025 | clinicaltrials |
| NCT03264547 | A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab | completed | Phase 3 | 446 | Japan Breast Cancer Research GroupOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT01650701 | A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma(RELEVANCE) | completed | Phase 3 | 1,030 | The Lymphoma Academic Research OrganisationOTHER | 8 | Sep 25, 2025 | clinicaltrials |
| NCT03367572 | Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer | completed | Phase 3 | 1,363 | University of Rochester NCORP Research BaseOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT00410761 | An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer | completed | Phase 3 | 331 | Genzyme, a Sanofi CompanyINDUSTRY | 24 | Sep 24, 2025 | clinicaltrials |
| NCT01999634 | Monitoring by Microdialysis of Postoperative Complications After Proctectomy(MTM-COLON-II) | completed | Phase 3 | 21 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT04186845 | Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence | completed | Phase 3 | 391 | Blue Earth DiagnosticsINDUSTRY | 3 | Sep 22, 2025 | clinicaltrials |
| NCT04487067 | A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista(AMETHISTA) | completed | Phase 3 | 152 | Hoffmann-La RocheINDUSTRY | 1 | Sep 22, 2025 | clinicaltrials |
| NCT00210210 | Administration of Ketamine to Prevent the Post-operative Pain(KETAMINE) | completed | Phase 3 | 230 | Institut BergoniéOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT01727388 | Informativeness to Digital Rectal Examination(RIFIONA) | completed | Phase 3 | 320 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT02839473 | Hydrosorb® Versus Control in the Management of Radio-induced Skin Toxicity: Multicentre Controlled Phase III Randomized Trial(HYDROSORB) | completed | Phase 3 | 278 | Institut CurieOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT04327063 | MIRs 04 : Interpectoral Nerve Block With Ropivacaine Versus Placebo Before Breast Cancer Surgery(MIRs 04) | completed | Phase 3 | 182 | Institut CurieOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06341998 | Clinical Study of Chemotherapy in the Treatment of Recurrent/Refractory Yolk Sac Tumor in Children(SCRRYST) | completed | Phase 2 / Phase 3 | 32 | Shandong First Medical UniversityOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06175273 | Pediatric Oncology Nutrition Intervention Trial(POINT) | completed | Phase 2 / Phase 3 | 19 | Corey HawesOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT01241708 | Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma((Mel/MelVel)) | completed | Phase 3 | 148 | Hackensack Meridian HealthOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT01120249 | S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery(S0931) | completed | Phase 3 | 1,545 | SWOG Cancer Research NetworkNETWORK | 2 | Sep 16, 2025 | clinicaltrials |
| NCT01351870 | Hyperfractionated Versus Conventionally Fractionated Radiotherapy in Standard Risk Medulloblastoma (PNET4)(SIOP-PNET-4) | completed | Phase 3 | 52 | Institut CurieOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT01811121 | MEDICO-ECONOMIC EVALUATION OF SURGERY GUIDED BY FLUORESCENCE FOR THE OPTIMIZATION OF RESECTION OF GLIOBLASTOMAS(RESECT) | completed | Phase 3 | 170 | Hospices Civils de LyonOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT03778931 | Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer(EMERALD) | completed | Phase 3 | 478 | Stemline Therapeutics, Inc.INDUSTRY | 17 | Sep 15, 2025 | clinicaltrials |
| NCT04908787 | A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer | completed | Phase 3 | 421 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 11, 2025 | clinicaltrials |
| NCT00532155 | A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer(VITAL) | completed | Phase 3 | 913 | SanofiINDUSTRY | 32 | Sep 10, 2025 | clinicaltrials |
| NCT02514681 | A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer(PRECIOUS) | completed | Phase 3 | 226 | Japan Breast Cancer Research GroupOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT03653546 | First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases(BM) | completed | Phase 2 / Phase 3 | 492 | Alpha Biopharma (Jiangsu) Co., Ltd.INDUSTRY | 4 | Sep 10, 2025 | clinicaltrials |
| NCT05590793 | Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate | completed | Phase 3 | 195 | IpsenINDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT04534075 | Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial(FIDURA) | completed | Phase 3 | 354 | Sahlgrenska University HospitalOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT00930033 | Clinical Trial to Assess the Importance of Nephrectomy(CARMENA) | completed | Phase 3 | 452 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT05889845 | Candin for the Treatment of Common Warts | completed | Phase 3 | 330 | Nielsen BioSciences, Inc.INDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT00186888 | Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma | completed | Phase 3 | 107 | St. Jude Children's Research HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT02136134 | Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 3 | 498 | Janssen Research & Development, LLCINDUSTRY | 15 | Aug 29, 2025 | clinicaltrials |
| NCT02330926 | Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy(MENAC) | completed | Phase 3 | 221 | Norwegian University of Science and TechnologyOTHER | 6 | Aug 29, 2025 | clinicaltrials |
| NCT02605265 | Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1(CinClare) | completed | Phase 3 | 356 | Fudan UniversityOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT04410133 | Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases(REVELATE) | completed | Phase 3 | 151 | Blue Earth DiagnosticsINDUSTRY | 1 | Aug 28, 2025 | clinicaltrials |
| NCT00278408 | Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma | completed | Phase 3 | 700 | German High-Grade Non-Hodgkin's Lymphoma Study GroupOTHER | 4 | Aug 26, 2025 | clinicaltrials |
| NCT04941300 | ColoRectal Cancer Screening for Southern California Community Health Centers | completed | Phase 3 | 55,999 | University of California, San DiegoOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT02752074 | A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301) | completed | Phase 3 | 706 | Incyte CorporationINDUSTRY | 23 | Aug 24, 2025 | clinicaltrials |
| NCT02195479 | A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma | completed | Phase 3 | 706 | Janssen Research & Development, LLCINDUSTRY | 24 | Aug 22, 2025 | clinicaltrials |
| NCT03588091 | Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer | completed | Phase 3 | 355 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Oct 14, 2025source: clinicaltrials